Loading organizations...
Rempex Pharmaceuticals is a technology company.
Rempex Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of novel antibacterial drugs. The company’s core work centers on creating new therapeutic agents, including advanced beta-lactamase inhibitors and antibiotics like Carbavance and Minocin IV, designed to combat the increasing threat of multi-drug resistant bacterial pathogens. Its technical approach emphasizes addressing challenging gram-negative infections, aiming to provide solutions where existing treatments are insufficient.
The company was founded in 2011 by Daniel Burgess, who served as its President and CEO. Burgess established Rempex Pharmaceuticals with the insight that a critical unmet medical need existed for effective treatments against bacteria evolving resistance to current antibiotics. His vision centered on developing a robust pipeline of anti-infective products to tackle this growing public health crisis, leveraging a deep understanding of antibiotic resistance mechanisms.
Rempex Pharmaceuticals' products are intended for healthcare providers and institutions grappling with severe bacterial infections, particularly those caused by drug-resistant strains. The company’s overarching mission is to deliver life-saving antimicrobial therapies that provide meaningful improvements in patient outcomes, thereby sustaining the effectiveness of antibiotic medicine for the future. It strives to equip clinicians with potent tools to overcome antimicrobial resistance.
Rempex Pharmaceuticals has raised $68.0M across 1 funding round.
Rempex Pharmaceuticals has raised $68.0M in total across 1 funding round.
Rempex Pharmaceuticals has raised $68.0M in total across 1 funding round.
Rempex Pharmaceuticals's investors include Frazier Healthcare Partners, OrbiMed, Adams Street Partners, SV Health Investors, Vivo Ventures.
Rempex Pharmaceuticals is a San Diego-based biopharmaceutical company specializing in the discovery and development of novel antibacterial drugs targeting multi-drug resistant gram-negative bacteria and other serious infections.[5][6][4] It develops innovative antibiotics like VABOMERE™ (meropenem and vaborbactam), ORBACTIV® (oritavancin), and formulations such as MINOCIN® for injection, addressing unmet needs in combating antibiotic resistance.[1] The company serves patients with life-threatening infections, particularly those caused by resistant pathogens, solving the critical problem of limited treatment options amid rising antimicrobial resistance (AMR).[1][4] Founded in 2011, Rempex achieved key FDA approvals through 2017 and secured partnerships like those with BARDA, though it was acquired by The Medicines Company in 2013 and operated as a subsidiary.[1]
Rempex Pharmaceuticals was founded in 2011 by leaders from prior antibiotic-focused ventures, including Microcide Pharmaceuticals (genomics-based discovery of efflux pump inhibitors and early anti-MRSA compounds) and Mpex Pharmaceuticals (developer of QUINSAIR® for cystic fibrosis infections, acquired in 2011).[1] These founders brought expertise from Shionogi's cephalosporin programs (e.g., ceftibuten in 1992) and responded to the 2009 launch of the Global Antibiotic Resistance Partnership (GARP), amid growing AMR threats highlighted by the CDC.[1] Early traction included discovering a new class of boronate beta-lactamase inhibitors, leading to vaborbactam's clinical development; the 2013 acquisition by The Medicines Company preserved operations as a wholly owned subsidiary.[1]
Rempex rides the global AMR crisis, exacerbated by CDC reports and initiatives like the 2016 Davos Declaration, where timing aligned with urgent calls for sustainable antibiotic markets.[1] Market forces favoring it include government funding (e.g., BARDA) and regulatory incentives for resistance-fighting drugs, positioning Rempex amid a biopharma shift toward targeted antimicrobials over broad-spectrum options.[1] It influences the ecosystem by validating beta-lactamase inhibitor tech, inspiring follow-on innovations from Qpex Biopharma (tracing Rempex roots) and contributing to the antibiotic stewardship movement.[1]
Post-2017 approvals, Rempex's trajectory likely integrates into broader portfolios following The Medicines Company's 2020 acquisition by Novartis, with potential for vaborbactam expansions or new resistant-pathogen indications.[1] Rising AMR trends, projected to cause 10 million annual deaths by 2050 without intervention, will shape its legacy through licensed tech sustaining treatments.[1] Its influence may evolve via ecosystem successors like Qpex, amplifying impact in an era of precision antibiotics—reinforcing Rempex's role as a pivotal player in averting a post-antibiotic future.[1]
Rempex Pharmaceuticals has raised $68.0M across 1 funding round. Most recently, it raised $68.0M Series B in November 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2011 | $68.0M Series B | Frazier Healthcare Partners, OrbiMed, Adams Street Partners, SV Health Investors, Vivo Ventures |